Longeveron, Inc.
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 2014
- Employees:
- 11-100
About Us
Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.
Our Facility
Longeveron’s corporate headquarters and manufacturing facilities are located in the Converge Miami Building in Miami, Florida. This state-of-the-art GMP facility consists of 3,000 ft2 of cleanroom space containing 8 ISO 7 cleanrooms and ancillary areas as well as 1,150 ft2 of process development, quality control and warehousing space. All products are manufactured and released based on FDA guidance to include 21 CFR 210, 211, 606 and 610.
Our History
Longeveron was founded on the premise that the very cells within our bodies whose primary function is to repair, restore and regenerate damaged tissue and organs may be developed into a safe and effective “off-the-shelf” cell therapy to treat chronic aging-related diseases and other life-threatening conditions, to improve healthspan, and to extend longevity.
Since our founding in 2014, we have focused our efforts on generating clinical safety and efficacy data in our selected indications, building, staffing and equipping a state-of-the art GMP manufacturing and research and development facility, expanding our intellectual property portfolio, developing and expanding our manufacturing processes and capabilities.
Our programs have been awarded more than $16.2 million in grant funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI) of NIH, the Alzheimer’s Association, and the Maryland Stem Cell Research Fund (MSCRF) of the Maryland TEDCO.
We manufacture our own product candidates for clinical research and product development in our GMP facility, comprised of eight clean rooms, two research and development laboratories, and warehouse and storage space. We have supply contracts with multiple third parties for fresh bone marrow, which we use to produce our lead therapeutic candidate called Lomecel-B™. From time to time we enter into contract development and manufacturing contracts or arrangements with third parties who seek to utilize our product development capabilities.
Our therapeutic indications currently under clinical study are:
- Hypoplastic Left Heart Syndrome
- Alzheimer’s Disease
- Aging Frailty
- Metabolic Syndrome
- Acute Respiratory Distress Syndrome due to COVID-19 or Influenza